AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of 287.99 billion. The enterprise value is 312.21 billion.
| Market Cap | 287.99B |
| Enterprise Value | 312.21B |
Important Dates
The last earnings date was Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | Aug 7, 2025 |
Share Statistics
| Current Share Class | 1.55B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 81.24% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 30.64 and the forward PE ratio is 18.93.
| PE Ratio | 30.64 |
| Forward PE | 18.93 |
| PS Ratio | 4.95 |
| PB Ratio | 6.26 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.75 |
| P/OCF Ratio | 19.02 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.26, with an EV/FCF ratio of 24.66.
| EV / Earnings | 33.22 |
| EV / Sales | 5.45 |
| EV / EBITDA | 15.26 |
| EV / EBIT | 19.92 |
| EV / FCF | 24.66 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.71.
| Current Ratio | 0.88 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | 2.58 |
| Interest Coverage | 12.24 |
Financial Efficiency
Return on equity (ROE) is 21.67% and return on invested capital (ROIC) is 13.16%.
| Return on Equity (ROE) | 21.67% |
| Return on Assets (ROA) | 9.06% |
| Return on Invested Capital (ROIC) | 13.16% |
| Return on Capital Employed (ROCE) | 19.78% |
| Revenue Per Employee | 616,405 |
| Profits Per Employee | 99,671 |
| Employee Count | 94,300 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.59 |
Taxes
In the past 12 months, AstraZeneca has paid 2.04 billion in taxes.
| Income Tax | 2.04B |
| Effective Tax Rate | 17.79% |
Stock Price Statistics
The stock price has increased by +43.37% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +43.37% |
| 50-Day Moving Average | 166.40 |
| 200-Day Moving Average | 150.29 |
| Relative Strength Index (RSI) | 73.16 |
| Average Volume (20 Days) | 1,421 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of 58.13 billion and earned 9.40 billion in profits. Earnings per share was 6.02.
| Revenue | 58.13B |
| Gross Profit | 48.40B |
| Operating Income | 15.91B |
| Pretax Income | 11.44B |
| Net Income | 9.40B |
| EBITDA | 20.42B |
| EBIT | 15.91B |
| Earnings Per Share (EPS) | 6.02 |
Balance Sheet
The company has 8.18 billion in cash and 32.66 billion in debt, giving a net cash position of -24.48 billion.
| Cash & Cash Equivalents | 8.18B |
| Total Debt | 32.66B |
| Net Cash | -24.48B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 45.97B |
| Book Value Per Share | 29.59 |
| Working Capital | -4.11B |
Cash Flow
In the last 12 months, operating cash flow was 15.14 billion and capital expenditures -2.48 billion, giving a free cash flow of 12.66 billion.
| Operating Cash Flow | 15.14B |
| Capital Expenditures | -2.48B |
| Free Cash Flow | 12.66B |
| FCF Per Share | n/a |
Margins
Gross margin is 83.26%, with operating and profit margins of 27.37% and 16.17%.
| Gross Margin | 83.26% |
| Operating Margin | 27.37% |
| Pretax Margin | 19.68% |
| Profit Margin | 16.17% |
| EBITDA Margin | 35.12% |
| EBIT Margin | 27.37% |
| FCF Margin | 21.78% |
Dividends & Yields
This stock pays an annual dividend of 3.13, which amounts to a dividend yield of 1.66%.
| Dividend Per Share | 3.13 |
| Dividend Yield | 1.66% |
| Dividend Growth (YoY) | 213.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 52.89% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 1.74% |
| Earnings Yield | 3.26% |
| FCF Yield | 4.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 7 |